Stage IV Lung Adenocarcinoma With KRAS Mutation Responding to Immunotherapy and Anti-Angiogenic Treatment
This lung cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Subtype
- Adenocarcinoma
- Biomarkers
- KRAS Q61H mutation; MET amplification
- Sex
- male
- Spread to
- pleura
- Treatment
- chemotherapy, immunotherapy, targeted therapy and radiation
- Outcome
- Responding Well
Treatment course, step by step
- Started cisplatin and pemetrexed with an anti-angiogenic treatment.
- After worsening pleural disease and malignant pleural effusion, treatment changed to cisplatin and docetaxel with camrelizumab and endostatin, and he also received 6 sessions of proton heavy-ion therapy.
- Continued camrelizumab with anti-angiogenic therapy, later switching from endostatin to bevacizumab.
What happened, in summary
A man was diagnosed in December 2020 with Stage IV lung adenocarcinoma after presenting with cough, sputum, chest tightness, pericardial fluid, and pleural effusion. Tumor testing identified a KRAS Q61H mutation and MET amplification.
He initially received cisplatin and pemetrexed with anti-angiogenic treatment. Within several months, pleural thickening and fluid increased, and he developed a malignant pleural effusion. His treatment was changed to cisplatin and docetaxel with camrelizumab immunotherapy and endostatin. He also received 6 sessions of proton heavy-ion therapy outside the treating hospital. After 12 cycles of immunotherapy, the anti-angiogenic component was changed from endostatin to bevacizumab while camrelizumab continued.
During treatment, a separate papillary thyroid cancer was discovered, but management focused on the more urgent lung cancer. By the December 2023 follow-up, the pleural effusion had disappeared, several tumor markers had returned to the normal range, and the primary lung tumor had not progressed. He was described as symptom-free and in good health while continuing maintenance therapy.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Stage 4 Lung Cancer 384 stories
- KRAS Mutation Lung Cancer 20 stories
- Bevacizumab for Lung Cancer 37 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer